Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Olanzapine Tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg (ANDA 091388). The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India.
Olanzapine Tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg are the generic equivalent of Eli Lilly & Company’s Zyprexa Tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg. Olanzapine Tablets are indicated for the treatment of serious psychotic disorders such as Schizophrenia and falls under the Neurological (CNS) therapeutic category. The annual sale of Olanzapine Tablets is approximately $3.2 billion and is ready for launch.
Aurobindo now has a total of 149 ANDA approvals (121 Final approvals including 1 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.
Aurobindo Pharma has a product presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc. The company is the market leader in semi-synthetic penicillin drugs.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: